X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glenmark Pharma Fact Sheet, Glenmark Pharma Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark Pharma Fact Sheet   (GLPH)

Here is the latest financial fact sheet of Glenmark Pharma. For more details, see the Glenmark Pharma quarterly results and Glenmark Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

GLENMARK PHARMA Price History

Price Rs 572.4
Mkt Cap Rs m 155,267
Vol '000 24.9
P/E X 13.1
P/CF X 11.3
EPS (TTM) Rs 43.7
% ch % 1.3
No. of shares m 271.28
% ch week % -1.6
% ch 1-mth % 4.7
% ch 12-mth % -37.0
52 week H/L Rs 930.0/517.4
(As on Apr 20, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

GLENMARK PHARMA Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
GLENMARK PHARMA EQUITY SHARE DATA
High Rs5516128791,262993 
Low Rs301464752672729 
Sales per share (Unadj.) Rs185.1221.4244.4271.1325.5 
Earnings per share (Unadj.) Rs23.220.117.526.339.3 
Diluted earnings per shareRs23.220.117.527.440.9 
Cash flow per share (Unadj.) Rs27.928.127.134.648.7 
Dividends per share (Unadj.) Rs2.002.002.002.002.00 
Adj. dividends per shareRs2.002.002.002.082.08 
Dividend yield (eoy) %0.50.40.20.20.2 
Book value per share (Unadj.) Rs102.0110.086.1128.6159.2 
Adj. book value per shareRs101.9110.086.1133.8165.6 
Shares outstanding (eoy) m270.85271.22271.29282.16282.17 
Bonus/Rights/Conversions  ----ESOP 
Price / Sales ratio x2.32.43.33.62.6 
Avg P/E ratio x18.426.746.636.721.9 
P/CF ratio (eoy) x15.319.130.127.917.7 
Price / Book Value ratio x4.24.99.57.55.4 
Dividend payout %8.69.911.47.65.1 
Avg Mkt Cap Rs m115,355145,889221,284272,778242,991 
No. of employees `000NANA9.510.013.0 
Total wages/salary Rs m7,83010,26212,02413,78216,408 
Avg. sales/employee Rs ThNMNM6,961.17,630.57,083.9 
Avg. wages/employee Rs ThNMNM1,262.51,374.81,265.4 
Avg. net profit/employee Rs ThNMNM499.0741.2855.1 
GLENMARK PHARMA INCOME DATA
Net Sales Rs m50,12360,05266,29876,49691,857 
Other income Rs m108115219200374 
Total revenues Rs m50,23160,16766,51676,69692,230 
Gross profit Rs m10,15310,90810,22514,37220,367 
Depreciation Rs m1,2702,1682,6002,3432,644 
Interest Rs m1,6001,8861,9021,7892,373 
Profit before tax Rs m7,3906,9695,94310,44015,724 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m0000-810 
Tax Rs m1,1071,5131,1903,0093,827 
Profit after tax Rs m6,2835,4564,7527,43011,088 
Gross profit margin %20.318.215.418.822.2 
Effective tax rate %15.021.720.028.824.3 
Net profit margin %12.59.17.29.712.1 
GLENMARK PHARMA BALANCE SHEET DATA
Current assets Rs m37,26847,62753,19959,04368,746 
Current liabilities Rs m22,01429,49237,11139,99327,027 
Net working cap to sales %30.430.224.324.945.4 
Current ratio x1.71.61.41.52.5 
Inventory Days Days6157707585 
Debtors Days Days11913113811996 
Net fixed assets Rs m27,68230,35717,44521,41624,132 
Share capital Rs m271271271282282 
"Free" reserves Rs m19,33821,41523,08636,01444,643 
Net worth Rs m27,63029,83323,35736,29644,925 
Long term debt Rs m19,20324,28725,74424,87345,363 
Total assets Rs m71,71086,33687,429101,929117,639 
Interest coverage x5.64.74.16.87.6 
Debt to equity ratio x0.70.81.10.71.0 
Sales to assets ratio x0.70.70.80.80.8 
Return on assets %11.08.57.69.011.4 
Return on equity %22.718.320.320.524.7 
Return on capital %19.216.416.020.019.1 
Exports to sales %11.911.744.843.20 
Imports to sales %1.71.07.17.40 
Exports (fob) Rs m5,9577,03929,72033,0440 
Imports (cif) Rs m8585794,6805,6720 
Fx inflow Rs m7,0078,52831,29936,94556,152 
Fx outflow Rs m4,1353,64110,85661,0668,084 
Net fx Rs m2,8724,88820,443-24,12248,068 
GLENMARK PHARMA CASH FLOW
From Operations Rs m 6,479 8,537 4,817 3,449 6,574 
From Investments Rs m -4,641 -3,681 -5,400 -8,802 -7,124 
From Financial Activity Rs m 1,952 -980 1,992 6,986 5,432 
Net Cashflow Rs m 2,851 1,896 -311 934 1,992 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 48.3%
Foreign collaborators 0.0%
Indian inst/Mut Fund 6.9%
FIIs 34.4%
ADR/GDR 0.0%
Free float 10.5%
Shareholders 56,727
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026
E-MAIL complianceofficer@glenmarkpharma.com WEB www.glenmarkpharma.com
TELEPHONE (022) 4018 9999 FAX (022) 4018 9986
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computer, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR Walker, Chandiok & Co.
CHM: Glenn Saldanha (MD) COMP SEC: Sanjay Kumar Chowdhary YEAR OF INC: 1977 BSE CODE: 532296 FV (Rs): 1 DIV YIELD (%): 0.4

More Pharmaceuticals Company Fact Sheets:   FULFORD INDIA  DR. REDDYS LAB  ALKEM LABORATORIES  J.B.CHEMICALS  ELDER PHARMA  

Compare GLENMARK PHARMA With:   FULFORD INDIA  DR. REDDYS LAB  ALKEM LABORATORIES  J.B.CHEMICALS  ELDER PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; IT Sector Ends 4.8% Higher(Closing)

After opening their day on a negative note, Indian share markets witnessed choppy trades and ended their session on a flat note.

Views on news

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Why 2.8 Crore Indians Applied for 90,000 Jobs in Indian Railways(Vivek Kaul's Diary)

Apr 16, 2018

This is an excellent example of the huge underemployment problem in India, which the Modi government refuses to acknowledge.

If Your Broker Calls You, Bang the Phone Down!(Smart Contrarian)

Apr 10, 2018

I'm going to tell you certain things about the inner workings of the industry so that you know why his advice is likely to be at best junk, and at worst dangerous.

How to Pick Great Stocks with Rajeev Thakkar(The 5 Minute Wrapup)

Apr 9, 2018

Rajeev Thakkar tells us how teachings from Vipassana can help you became a better investor.

How Small Caps Can Change the Way You Eat, Sleep, and Drive(Sector Info)

Apr 11, 2018

How you can increase your odds of seizing multibagger stocks and rake in the moolah by investing in small cap stocks.

This is How a Smart Robo-Advisor can Help You Chart Your Asset Allocation...(Outside View)

Apr 16, 2018

PersonalFN explains how a dependable robo-advisory platform can help you create your personalized asset allocation plan

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS